Shares of Eli Lilly LLY fell 5.2% in pre-market trading after the company reported Q1 results.
Quarterly Results
Earnings per share rose 6.86% year over year to $1.87, which missed the estimate of $2.14.
Revenue of $6,805,600,000 higher by 16.14% from the same period last year, which missed the estimate of $7,020,000,000.
Outlook
The upcoming fiscal year's EPS expected to be between $7.80 and $8.00.
The upcoming fiscal year's revenue expected to be between $26,600,000,000 and $27,600,000,000.
How To Listen To The Conference Call
Date: Apr 27, 2021
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/33jpbzig
Price Action
52-week high: $218.00
52-week low: $129.21
Price action over last quarter: down 12.62%
Company Description
Eli Lilly is a drug company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
